METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: targeted pill plus chemotherapy in Late-Stage trial
Disease control Recruiting nowThis Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental drug combo enters large trial
Disease control Recruiting nowThis large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug targets genetic weakness in tough pancreatic cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a new drug combo tame pancreatic cancer and prevent clots?
Disease control Recruiting nowThis early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common comp…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Supercharged immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the righ…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Anocca AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for pancreatic cancer: dual antibody plus targeted pill tested in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether a new combination of drugs—TQB2868 (a dual antibody) plus anlotinib capsules—works better than standard chemotherapy for people with metastatic pancreatic cancer that has spread. About 566 participants will be randomly assigned to receive either t…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to outsmart pancreatic Cancer's defenses
Disease control Recruiting nowThis study is for people with metastatic pancreatic cancer that has worsened after initial treatment. It tests a new drug, ONT01, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) to see if it can reprogram immune cells in the tumor to fight cancer better. Abou…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cocktail aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and i…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to boost chemo for tough pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental MK2 inhibitor (zunsemetinib) to standard chemotherapy (mFOLFIRINOX) can better control metastatic pancreatic cancer. About 51 adults who have not had prior treatment for advanced disease will participate. The main goals …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can surgery beat pancreatic cancer spread? new trial aims to find out
Disease control Recruiting nowThis trial tests whether removing both the main pancreatic tumor and small spots in the liver or lungs after chemotherapy can help patients. It includes 40 people whose cancer has spread to only a few spots. Everyone gets the same treatment: chemo first, then surgery if the cance…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could two old drugs boost chemo for pancreatic cancer?
Disease control Recruiting nowThis phase 2 trial tests whether adding valproic acid and simvastatin to standard chemotherapy can help people with untreated metastatic pancreatic cancer live longer without their disease getting worse. About 240 participants will be randomly assigned to receive either the stand…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktails aim to shrink Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a drug combo tame deadly pancreatic cancer?
Disease control Recruiting nowThis large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo.…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental combo aims to overcome drug resistance in metastatic cancers
Disease control Recruiting nowThis early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New MRI scan could predict pancreatic cancer treatment success
Diagnosis Recruiting nowThis study tests an experimental MRI scan that uses a special contrast agent called hyperpolarized carbon-13 pyruvate to see how pancreatic tumors process nutrients. The goal is to find out if this scan can predict treatment response better than standard MRIs. About 70 adults wit…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New drug aims to fight deadly wasting in pancreatic cancer patients
Symptom relief Recruiting nowThis study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jul 02, 2026 03:00 UTC
-
Personalized medicine hope: genetic screening for pancreatic cancer
Knowledge-focused Recruiting nowThis study looks at the genes of 750 people with advanced or metastatic pancreatic cancer. The goal is to find specific genetic changes that could help doctors choose better treatments, like targeted drugs or chemotherapy combinations. Participants must have a tumor sample availa…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New drug OMO-103 tested in early pancreatic cancer trial
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after trea…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Pancreatic cancer drugs put to the test in early trial
Knowledge-focused Recruiting nowThis early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Pancreatic cancer gene study aims to personalize care
Knowledge-focused Recruiting nowThis study looks at genetic changes in metastatic pancreatic cancer to see if they can help guide treatment choices. Researchers will take tumor biopsies and blood samples from 190 patients starting chemotherapy. The main goal is to see if genetic test results can be returned wit…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Blood test may speed up chemo decisions for deadly pancreatic cancer
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The trial will enroll 50 people w…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC